Cureline

Cureline operates as a specialized human biospecimen CRO and biobank, serving pharmaceutical, biotech, and academic clients worldwide. The company leverages a global clinical network across 20 countries to procure high-quality, annotated tissues and biofluids, supporting over 4,000 projects for more than 700 clients since its inception. Its integrated 'Tissue 2 Target' service model combines biospecimen access with downstream molecular, histopathology, and biomarker validation services, positioning it as a collaborative partner in precision medicine R&D. While not developing its own therapeutics, Cureline's platform is foundational for translational research and companion diagnostic development.

Integrated global network for human biospecimen (HBS) procurement, biobanking, and analysis under the 'Tissue 2 Target' service model. Includes molecular profiling, histopathology, digital pathology, tissue microarray, and biomarker validation services.

Cureline competes in the human biospecimen and translational research services market against large, full-service CROs (e.g., LabCorp, IQVIA), specialty biorepositories, and academic tissue banks. Its differentiation lies in its focused 'Tissue 2 Target' integration, deep oncology expertise, and two-decade track record, including contributions to major projects like TCGA.